A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug

Inclusion Criteria:

- Seropositive for HCMV IgG antibodies before transplantation

- First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of
the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's
lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder

- Evidence of post transplantation engraftment

- Able to swallow tablets.

Exclusion Criteria:

- Previous anti-HCMV therapy after this allogeneic HBPC transplantation

- Mismatched or cord blood transplant recipients

- Current or history of end-organ HCMV disease

- Graft versus host disease (GVHD)

- Impaired liver function

- Reduced renal function